127 related articles for article (PubMed ID: 2450434)
1. Morphometric differences between cytologically benign and malignant serous effusions.
Gavin FM; Gray C; Sutton J; Clayden AD; Banks RI; Bird CC
Acta Cytol; 1988; 32(2):175-82. PubMed ID: 2450434
[TBL] [Abstract][Full Text] [Related]
2. Role of computerized morphometric analysis in diagnosis of effusion specimens.
Arora B; Setia S; Rekhi B
Diagn Cytopathol; 2006 Oct; 34(10):670-5. PubMed ID: 16955473
[TBL] [Abstract][Full Text] [Related]
3. The cytologic application of carcinoembryonic antigen for the discrimination of malignant from benign serous effusions.
Kyrkou KA; Iatridis SG; Athanassiadou PP; Athanassiadis PP; Mandragos CE
Cancer Detect Prev; 1985; 8(1-2):247-54. PubMed ID: 4064045
[TBL] [Abstract][Full Text] [Related]
4. Morphometric diagnosis of serous effusions: refinement of differences between benign and malignant cases by use of outlying values and larger sample size.
Scott N; Sutton J; Gray C
J Clin Pathol; 1989 Jun; 42(6):607-12. PubMed ID: 2738165
[TBL] [Abstract][Full Text] [Related]
5. The cytologic diagnosis of malignant neoplasms in pleural and peritoneal effusions.
Sears D; Hajdu SI
Acta Cytol; 1987; 31(2):85-97. PubMed ID: 3469856
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic approach of effusion cytology using computerized image analysis.
Athanassiadou P; Kavantzas N; Davaris P; Gonidi M; Liossi A; Nakopoulou L; Petrakakou E; Athanassiades P
J Exp Clin Cancer Res; 2002 Mar; 21(1):49-56. PubMed ID: 12071529
[TBL] [Abstract][Full Text] [Related]
7. Telomerase activity in benign and malignant cytologic fluids.
Mu XC; Brien TP; Ross JS; Lowry CV; McKenna BJ
Cancer; 1999 Apr; 87(2):93-9. PubMed ID: 10227600
[TBL] [Abstract][Full Text] [Related]
8. Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions.
Afify A; Lynne LC; Howell L
Diagn Cytopathol; 2007 Feb; 35(2):105-10. PubMed ID: 17230576
[TBL] [Abstract][Full Text] [Related]
9. Positive effusion cytology as the initial presentation of malignancy.
Monte SA; Ehya H; Lang WR
Acta Cytol; 1987; 31(4):448-52. PubMed ID: 3604540
[TBL] [Abstract][Full Text] [Related]
10. An immunoperoxidase study of S-100 protein in neoplastic cells in serous effusions. Use as a marker for melanoma.
Pinto MM
Acta Cytol; 1986; 30(3):240-4. PubMed ID: 3521174
[TBL] [Abstract][Full Text] [Related]
11. Significance of pericellular lacunae in cell blocks of effusions.
Price BA; Ehya H; Lee JH
Acta Cytol; 1992; 36(3):333-7. PubMed ID: 1580117
[TBL] [Abstract][Full Text] [Related]
12. [Contribution of immunocytochemical marking of benign cells to the diagnosis of serous effusions].
Gaulier A; Cava E; Chosia MC; Pore G; Marsan C
Ann Pathol; 1986; 6(4-5):323-8. PubMed ID: 3814272
[TBL] [Abstract][Full Text] [Related]
13. Interphase nucleolar organizer regions in the evaluation of serosal cavity effusions.
Carrillo R; Sneige N; el-Naggar AK
Acta Cytol; 1994; 38(3):367-72. PubMed ID: 8191825
[TBL] [Abstract][Full Text] [Related]
14. Pericellular lacunae in the diagnosis of metastatic carcinoma in effusions: is this a useful sign?
Thomson T; Hayes MM
Diagn Cytopathol; 1996 Sep; 15(3):193-6. PubMed ID: 8955600
[TBL] [Abstract][Full Text] [Related]
15. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
16. Serous effusions in malignant lymphomas: a review.
Das DK
Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
[TBL] [Abstract][Full Text] [Related]
17. Effusion cytology.
Ehya H
Clin Lab Med; 1991 Jun; 11(2):443-67. PubMed ID: 1873966
[TBL] [Abstract][Full Text] [Related]
18. Cytologic diagnosis and chromosome analysis: sensitivity, specificity, accuracy and predictive value in malignant and benign pleural effusions.
Giazza G; Cosimi MF; Lanero M; Rossi GP; Casagranda I
Pathologica; 1990; 82(1077):33-40. PubMed ID: 2362783
[TBL] [Abstract][Full Text] [Related]
19. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
20. The interval between the diagnosis of malignancy and the development of effusions, with reference to the role of cytologic diagnosis.
van de Molengraft FJ; Vooijs GP
Acta Cytol; 1988; 32(2):183-7. PubMed ID: 3348059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
